Envista Holdings Corporation (NVST) Stock Price & How to Invest

Envista Holdings Corporation is a Brea, California dental products maker spun out of Danaher in 2019, selling into more than 130 countries through roughly 30 brands: Nobel Biocare and Implant Direct in implants, Ormco and Spark in orthodontics, DEXIS in imaging, and Kerr in consumables. Two reporting segments carry the business. Specialty Products & Technologies (implants, prosthetics, brackets, aligners, lab products) generated ~$1.75 billion of 2025 sales, while Equipment & Consumables (imaging systems and software, bonding agents, rotary burs, endodontic systems, infection prevention) generated ~$967 million. Around 85% of revenue comes from consumables, services and spare parts rather than capital equipment, which gives the top line a recurring shape even in quarters when dentists defer large purchases. By region, North America contributed ~$1.40 billion of 2025 sales, Western Europe ~$615 million, and emerging markets ~$586 million.

The investment picture is a margin repair now several quarters old. 2024 was the trough: Envista withdrew its full-year guidance, wrote off $1.15 billion of goodwill and intangible assets, and reported a GAAP loss of $6.50 per share. Under CEO Paul Keel, who took the job that year, full-year 2025 produced 6.5% core sales growth, adjusted EBITDA of $372 million (up 26%) and adjusted EPS of $1.19. Momentum carried forward: first-half 2026 sales rose 10.5% to ~$1.44 billion with 7.1% core growth, adjusted EBITDA reached $207 million, and on August 5, 2026 management raised full-year guidance to 3.5% to 4.5% core sales growth and $1.50 to $1.55 in adjusted EPS. A wide gap persists between adjusted and GAAP results, driven mostly by intangible amortization, restructuring charges and an unusually high effective tax rate, so which figure an investor anchors on changes the valuation conclusion substantially.

Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. Emerging markets, about 22% of 2025 sales, carry specific pricing pressure: China's volume-based procurement program has forced steep price cuts on dental consumables and implants, and first-half 2026 emerging-market core growth was 0.8% against 8.5% in developed markets. Goodwill and other intangibles still total roughly $3.0 billion on a $5.6 billion balance sheet after the 2024 write-down, so another demand shock could produce a second impairment. Following the April 2024 guidance withdrawal, several plaintiff law firms publicised investigations of potential securities claims; Envista's fiscal 2025 Form 10-K and its second-quarter 2026 Form 10-Q name no securities class action, state that legal proceedings have not materially changed, and carry a $26.3 million accrual covering all litigation matters combined. Roughly half of revenue is earned outside the United States and a single customer accounted for 13% of second-quarter sales, so currency translation and distributor inventory swings can each move reported results independently of underlying demand.

14 analysts publish price targets on NVST, averaging $30.57 against a $27.64 price as of August 2026, or +10.6%. The published targets run from $23.00 to $35.00, a moderate spread, and the ratings split 7 buy, 9 hold, 0 sell. Over the last six months there have been 6 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NVST forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Envista Holdings Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Margin repair from a low base. Adjusted EBITDA margin moved from 11.8% in 2024 to 13.7% in 2025 and 14.7% in the second quarter of 2026, an expansion management credits to the Envista Business System, a 10% reduction in company-wide G&A, and the Spark aligner business reaching positive operating margin in the second half of 2025. The most optimistic published target, $35.00, assumes this works close to its best case.

The case against. Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. The most pessimistic target, $23.00, is roughly what NVST is worth if this bites instead.

Read the full bull and bear case on NVST, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Envista Holdings Corporation's investor relations page or your broker.

• Revenue (TTM): ~$2.86 billion
• Market cap: ~$4.44 billion (~$27.70 per share, ~160.6 million shares)
• Adjusted diluted EPS (TTM): ~$1.46 vs ~$0.58 on a GAAP basis
• Forward P/E on 2026 adjusted EPS guidance: ~18x ($1.50 to $1.55)
• EV / adjusted EBITDA (TTM): ~11x (~$4.75 billion EV, ~$416 million EBITDA)
• Net debt: ~$310 million, roughly 0.7x adjusted EBITDA

Two very different multiples describe the same stock: about 49x trailing GAAP earnings, and about 18x the midpoint of management's 2026 adjusted EPS guidance. Bridging them are amortization of acquired intangibles, restructuring charges, and a 2025 effective tax rate near 73% created by US pre-tax losses sitting alongside $203.9 million of international pre-tax income. At roughly 1.6x trailing sales and 1.5x book value, the market is not paying a premium on revenue or assets, the usual shape for a company whose reported earnings lag its operating improvement.

Other names that sit close to NVST: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NVST exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NVST sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NVST fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Envista is a recovery story valued on adjusted numbers, near 18x the midpoint of 2026 adjusted EPS guidance, where the operating improvement is measurable and reported GAAP earnings have not caught up with it.

Whether NVST is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NVST a buy or a sell?, and where the stock could go from here in the NVST stock forecast.

For income investors, whether NVST pays a dividend and how the payout looks is covered in does NVST pay a dividend? And to weigh NVST against a peer, read the full side-by-side comparisons: NVST vs ALGN and NVST vs SOLV.